Dear Editor, The increased morbidity andmortality due to hepatitis B virus (HBV)-related adverse events following hematopoietic stem cell transplantation (HSCT) have raised questions regarding its efficacy and widespread adoption especially in areas with intermediate and high levels of endemicity for HBV infection [1, 2]. We read with great interest Ahmet et al. study published ahead of print on July 31, 2020, in Annals of Hematology [3].
Correspondence in reference to the previously published Epub manuscript: “Murt Ahmet et al. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country. Annals of Hematology 2020; 99: 2671-2677” / Picardi, M.; Giordano, C.; Pepa, R. D.; Pugliese, N.; Leone, A.; Gentile, G.; Pane, F.. - In: ANNALS OF HEMATOLOGY. - ISSN 0939-5555. - 99:(2021), pp. 2671-2677. [10.1007/s00277-021-04436-9]
Correspondence in reference to the previously published Epub manuscript: “Murt Ahmet et al. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country. Annals of Hematology 2020; 99: 2671-2677”
Gentile G.;
2021
Abstract
Dear Editor, The increased morbidity andmortality due to hepatitis B virus (HBV)-related adverse events following hematopoietic stem cell transplantation (HSCT) have raised questions regarding its efficacy and widespread adoption especially in areas with intermediate and high levels of endemicity for HBV infection [1, 2]. We read with great interest Ahmet et al. study published ahead of print on July 31, 2020, in Annals of Hematology [3].I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
